| Quote
: |
冯忘忧,姜东伯,徐盈,李佳,杨红.SPOCK2在泛癌中的预后和免疫治疗反应中的潜在价值研究[J].湖南中医药大学学报英文版,2023,43(11):2071-2080.[Click to copy
] |
|
| |
|
|
| This paper
：Browser 986times Download 337times |
| SPOCK2在泛癌中的预后和免疫治疗反应中的潜在价值研究 |
| 冯忘忧,姜东伯,徐盈,李佳,杨红 |
| (空军军医大学西京医院妇产科, 陕西 西安 710032;空军军医大学基础医学院, 陕西 西安 710032) |
| 摘要: |
| 目的 探索睾丸蛋白聚糖2(sparc/osteonectin,cwcv and kazal-like domains proteoglycan 2, SPOCK2)在泛癌中的预后及免疫治疗反应中的作用。方法 基于癌症基因组图谱(The Cancer Genome Atlas, TCGA)和临床蛋白质组学肿瘤分析联盟(Clinical Proteomic Tumor Analysis Consortium, CPTAC)数据库检测SPOCK2在肿瘤组织与正常组织中的表达差异,并通过人类蛋白质图谱(Human Protein Atlas, HPA)数据库SPOCK2进行初步验证。关于SPOCK2对患者生存预后的影响采用Kaplan-Meier方法进行分析。采用基因富集工具进一步分析SPOCK2在肿瘤中参与的通路。最后通过桑格数据库研究SPOCK2与免疫细胞及免疫相关基因的关系。结果 SPOCK2在14种肿瘤中高表达,在12种肿瘤中低表达,且HPA数据库显示在肝细胞性肝癌、甲状腺癌、皮肤黑色素瘤及卵巢浆液性囊腺癌中SPOCK2高表达,与基因表达水平分析结果一致。生存分析结果表明SPOCK2高表达在多种肿瘤中预示预后良好。富集分析发现SPOCK2参与T细胞和辅助性T细胞的分化和激活过程。此外,与免疫浸润细胞的相关性分析显示SPOCK2水平与多数肿瘤中的B淋巴细胞、CD4+ T淋巴细胞、CD8+ T淋巴细胞和树突状细胞等免疫细胞浸润呈正相关。SPOCK2的表达水平与免疫调节因子和免疫检查点相关基因存在密切联系。结论 SPOCK2在泛癌中是一种免疫相关的生物标志物,具有调节肿瘤免疫微环境的作用,在免疫治疗中具有潜在的价值。 |
| 关键词: TCGA 免疫治疗 SPOCK2 泛癌 预后 免疫微环境 |
| DOI：10.3969/j.issn.1674-070X.2023.11.021 |
| Received:March 09, 2023 |
| 基金项目:国家自然科学基金项目（82172993）；陕西省自然科学基础研究计划一般项目（2022JQ-977）。 |
|
| Potential value of SPOCK2 in prognosis and immunotherapy response in pan-cancer |
| FENG Wangyou,JIANG Dongbo,XU Ying,LI Jia,YANG Hong |
| (Department of Obstetrics and Gynaecology, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi 710032, China;Basic Medical Science Academy, Air Force Medical University, Xi'an, Shaanxi 710032, China) |
| Abstract: |
| Objective To explore the role of sparc/osteonectin, cwcv, and kazal-like domains proteoglycan 2 (SPOCK2) in prognosis and immunotherapy response in pan-cancer. Methods The differential expressions of SPOCK2 in tumor tissues and normal tissues were examined by The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC), and SPOCK2 was preliminarily validated by the Human Protein Atlas (HPA). The effects of SPOCK2 on the survival and prognosis of patients were analyzed using the Kaplan-Meier method, and gene enrichment tools were used to further analyze the pathways involved in SPOCK2 in tumors. Finally, the Sanger database was used to study the relationship between SPOCK2 and the immune cells as well as immune-related genes. Results SPOCK2 was highly expressed in 14 tumors and lowly expressed in 12. HPA showed high expression of SPOCK2 in hepatocellular carcinoma, thyroid cancer, cutaneous melanoma, and ovarian serous cystadenocarcinoma, which was consistent with the analysis of gene expression levels. Survival analysis showed that high expression of SPOCK2 predicted good prognosis in multiple tumors, and enrichment analysis indicated that SPOCK2 was involved in the differentiation and activation of T cells and helper T cells. In addition, correlation analysis with immune infiltrating cells revealed that SPOCK2 level was positively correlated with the infiltration of immune cells such as B lymphocytes, CD4+ T lymphocytes, CD8+ T lymphocytes, and dendritic cells in most tumors. The expression levels of SPOCK2 were closely related to immune regulatory factors and immune checkpoint-related genes. Conclusion SPOCK2 is an immune-related biomarker in pan-cancer, which plays a role in regulating tumor immune microenvironment and has potential value in immunotherapy. |
| Key words: The Cancer Genome Atlas immunotherapy sparc/osteonectin, cwcv, and kazal-like domains proteoglycan 2 pan-cancer prognosis immune microenvironment |
|
二维码（扫一下试试看！） |
|
|
|
|
